These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35631676)

  • 1. Pharmacokinetic/Pharmacodynamic Evaluation of a New Purine-2,6-Dione Derivative in Rodents with Experimental Autoimmune Diseases.
    Świerczek A; Pociecha K; Plutecka H; Ślusarczyk M; Chłoń-Rzepa G; Wyska E
    Pharmaceutics; 2022 May; 14(5):. PubMed ID: 35631676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic/Pharmacodynamic Assessment of Selective Phosphodiesterase Inhibitors in a Mouse Model of Autoimmune Hepatitis.
    Świerczek A; Pomierny B; Wyska E; Jusko WJ
    J Pharmacol Exp Ther; 2022 May; 381(2):151-163. PubMed ID: 35221290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative assessment of PDE 4 and 7 inhibitors as therapeutic agents in experimental autoimmune encephalomyelitis.
    González-García C; Bravo B; Ballester A; Gómez-Pérez R; Eguiluz C; Redondo M; Martínez A; Gil C; Ballester S
    Br J Pharmacol; 2013 Oct; 170(3):602-13. PubMed ID: 23869659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Assessment of the New PDE7 Inhibitor - GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach.
    Świerczek A; Pociecha K; Ślusarczyk M; Chłoń-Rzepa G; Baś S; Mlynarski J; Więckowski K; Zadrożna M; Nowak B; Wyska E
    Pharm Res; 2020 Jan; 37(2):19. PubMed ID: 31899535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PK/PD Modeling of the PDE7 Inhibitor-GRMS-55 in a Mouse Model of Autoimmune Hepatitis.
    Świerczek A; Plutecka H; Ślusarczyk M; Chłoń-Rzepa G; Wyska E
    Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33919375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions.
    Szczypka M
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New imidazopyridines with phosphodiesterase 4 and 7 inhibitory activity and their efficacy in animal models of inflammatory and autoimmune diseases.
    Ručilová V; Świerczek A; Vanda D; Funk P; Lemrová B; Gawalska A; Bucki A; Nowak B; Zadrożna M; Pociecha K; Soural M; Wyska E; Pawłowski M; Chłoń-Rzepa G; Zajdel P
    Eur J Med Chem; 2021 Jan; 209():112854. PubMed ID: 33022582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in vitro evaluation of anti-inflammatory, antioxidant, and anti-fibrotic effects of new 8-aminopurine-2,6-dione-based phosphodiesterase inhibitors as promising anti-asthmatic agents.
    Wójcik-Pszczoła K; Jankowska A; Ślusarczyk M; Jakieła B; Plutecka H; Pociecha K; Świerczek A; Popiół J; Koczurkiewicz-Adamczyk P; Wyska E; Pękala E; Gosens R; Chłoń-Rzepa G
    Bioorg Chem; 2021 Dec; 117():105409. PubMed ID: 34749117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, Anti-inflammatory Activity and Docking Studies of Some Newer 1,3-Thiazolidine-2,4-dione Derivatives as Dual Inhibitors of PDE4 and PDE7.
    Sharma H; Lather V; Grewal AS; Pandita D
    Curr Comput Aided Drug Des; 2019; 15(3):225-234. PubMed ID: 30280674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico and in vitro ADME-Tox analysis and in vivo pharmacokinetic study of representative pan-PDE inhibitors from the group of 7,8-disubstituted derivatives of 1,3-dimethyl-7H-purine-2,6-dione.
    Wójcik-Pszczoła K; Szafarz M; Pociecha K; Słoczyńska K; Piska K; Koczurkiewicz-Adamczyk P; Kocot N; Chłoń-Rzepa G; Pękala E; Wyska E
    Toxicol Appl Pharmacol; 2022 Dec; 457():116318. PubMed ID: 36414119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphodiesterases do not limit beta1-adrenoceptor-mediated sinoatrial tachycardia: evidence with PDE3 and PDE4 in rabbits and PDE1-5 in rats.
    Kaumann AJ; Galindo-Tovar A; Escudero E; Vargas ML
    Naunyn Schmiedebergs Arch Pharmacol; 2009 Nov; 380(5):421-30. PubMed ID: 19693491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of phosphodiesterase 7 (PDE7) inhibitors in experimental autoimmune encephalomyelitis mice. Discovery of a new chemically diverse family of compounds.
    Redondo M; Brea J; Perez DI; Soteras I; Val C; Perez C; Morales-García JA; Alonso-Gil S; Paul-Fernandez N; Martin-Alvarez R; Cadavid MI; Loza MI; Perez-Castillo A; Mengod G; Campillo NE; Martinez A; Gil C
    J Med Chem; 2012 Apr; 55(7):3274-84. PubMed ID: 22385507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.
    Redondo M; Palomo V; Brea J; Pérez DI; Martín-Álvarez R; Pérez C; Paúl-Fernández N; Conde S; Cadavid MI; Loza MI; Mengod G; Martínez A; Gil C; Campillo NE
    ACS Chem Neurosci; 2012 Oct; 3(10):793-803. PubMed ID: 23077723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of LY2775240, a selective phosphodiesterase-4 inhibitor, in nonclinical models and in healthy subjects.
    Patel DR; Urva S; Ho S; Buckman CJ; Ma Y; Lim J; Sissons SE; Zuniga MS; Philips D; Cox K; Dairaghi DJ
    Clin Transl Sci; 2021 May; 14(3):1037-1048. PubMed ID: 33382916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of cAMP accumulation and activity by distinct phosphodiesterase subtypes in INS-1 cells and human pancreatic β-cells.
    Pratt EPS; Harvey KE; Salyer AE; Hockerman GH
    PLoS One; 2019; 14(8):e0215188. PubMed ID: 31442224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-Adrenergic cAMP signals are predominantly regulated by phosphodiesterase type 4 in cultured adult rat aortic smooth muscle cells.
    Zhai K; Hubert F; Nicolas V; Ji G; Fischmeister R; Leblais V
    PLoS One; 2012; 7(10):e47826. PubMed ID: 23094097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro differentiation of human monocytes to macrophages: change of PDE profile and its relationship to suppression of tumour necrosis factor-alpha release by PDE inhibitors.
    Gantner F; Kupferschmidt R; Schudt C; Wendel A; Hatzelmann A
    Br J Pharmacol; 1997 May; 121(2):221-31. PubMed ID: 9154331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel phosphodiesterases inhibitors from the group of purine-2,6-dione derivatives as potent modulators of airway smooth muscle cell remodelling.
    Wójcik-Pszczoła K; Chłoń-Rzepa G; Jankowska A; Ellen E; Świerczek A; Pociecha K; Koczurkiewicz P; Piska K; Gawędzka A; Wyska E; Knapik-Czajka M; Pękala E; Gosens R
    Eur J Pharmacol; 2019 Dec; 865():172779. PubMed ID: 31705904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of
    Ayyar VS; Song D; Zheng S; Carpenter T; Heald DL
    J Pharmacol Exp Ther; 2021 Nov; 379(2):134-146. PubMed ID: 34413198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor.
    Gu Y; Sai Y; Wang J; Yu M; Wang G; Zhang L; Ren H; Fan S; Ren Y; Qing W; Su W
    Eur J Pharm Sci; 2019 Aug; 136():104938. PubMed ID: 31132401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.